Bone Abstracts

In XLH, high circulating FGF23 causes hypophosphatemia, rickets, and short stature. In our Phase 2 study, 52 XLH children (ages 5-12 years, ≥Tanner 2) were randomized to receive KRN23 subcutaneously biweekly (Q2W) or monthly (Q4W). Serum phosphate (Pi) was measured biweekly. KRN23 dose was titrated (maximum 2 mg/kg) targeting age-appropriate serum Pi concentrations.The first 36 subjects had a mean 6.6 years of standard-of-care treatment before wash...

Objectives: Spinal muscular atrophy (SMA) results in varying degrees of hypotonic immobility. Prior reports demonstrate an increased risk of fracture and a trend toward low bone mineral density (BMD) in this population. We aim to further characterize bone health in paediatric SMA patients by reporting the prevalence of fractures and low BMD (z-score≤−2.0) by SMA subtype, BMD of the lateral distal femur (LDF; an important fracture location in non-ambulatory...

The aim of the study was to evaluate the appendicular lean mass depending on the dietary protein intake in the Ukrainian postmenopausal women.Materials and methods: The study involved 63 women aged 52–89 years, who, depending on their ages, were divided into groups: 52–59 years (n=9), 60–69 years (n=26), 70–79 years (n=21), 80–89 years (n=7). To assess the dietary habits of women, we used the t...

Objectives: Asfotase alfa (AA), an enzyme replacement therapy, is the only approved medical treatment for pediatric-onset hypophosphatasia (HPP), which is caused by deficient tissue-nonspecific alkaline phosphatase activity. We detail the long-term efficacy of AA observed from the pediatric clinical trial program.Methods: Efficacy data collected to study completion were pooled from 3 open-label, multicenter investigations of children who manifested HPP s...

Low fracture (FX) incidence has been demonstrated in women with postmenopausal osteoporosis (PMO) treated with DMAb for up to 10 years in the FREEDOM extension [Bone ASBMR 2015]. Bone biopsy-based assessment of DMAb’s effects at the tissue level has demonstrated a low remodelling rate consistent with DMAb’s mechanism of action (Reid JBMR 2010; Brown JBMR 2014). From FREEDOM, we report the effects of DMAb on bone matrix mineralization in women who un...

Introduction: We aimed to study acceptability of zoledronic acid in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, biochemical, shipping registration at poll by phone and on the subsequent visits.Results: We studied 225 patients with postmenopausal osteoporosis. The patients were treated with zoledronic acid (Zol) 5 mg as a once-yearly infusion within 3 years and 2500 mg of calcium carbonate+800 ME v...

Objectives: A role for glucose-dependent insulinotropic polypeptide (GIP) in controlling bone mass and strength has previously been reported. However, the rapid degradation of GIP in the bloodstream by the dipeptidyl peptidase-4 enzyme precludes therapeutic use. To circumvent this problem, a series of N-terminally modified GIP agonists have been developed. The aim of the present study was to investigate the effects of 28-day treatment with N-AcGIP on bone microarchitecture and...

We previously evidenced a reduced response to i.v. pamidronate in Q15STM1 mutation carriers (Q15STM1+) with Paget’s disease of bone (PDB). In order to confirm and extend this observation, we investigated the effect of Q15STM1 mutation and polymorphisms in three genes associated with PDB (TNFRSF11A; OPTN; TNFRSF11B) on the response to bisphosphonates. First, a retrospective study was performed in 335 patients treated wi...

Osteoarthritis and osteoporosis are two elderly conditions characterized by two different pathophysiological mechanisms. In patients with chronic kidney disease (CKD), there is a metabolic impairment of the muscular-skeletal tissue. The aim of our study is to evaluate the biochemical and morphostructural alterations in different states of CKD in patients with osteoarthritis or hip fracture.We evaluated all patients undergoing hip replacement surgery from...

Objectives: To determine the prevalence and intensity of D-deficiency in children and adolescents in the metropolitan area with subtotal deficiency of ultraviolet B (55° N).Methods: From May 2008 to May 2010 in a random sample of 163 Muscovites 0–18 years old (9.9±0.4; girls/boys, 81/82) serum 25-hydroxyvitamin D content was determined by chemiluminescent analysis (DiaSorin, Inc., USA; n=56 and Roche Diagnostics; n=107). ...